Shire posts better-than-expected 13 percent rise in fourth-quarter earnings

LONDON (Reuters) – Shire , the London-listed drugmaker buying BaxaltaInternational for $32 billion, reported a better-than-expected 13 percent rise in fourth-quarter earnings on Thursday, helped by strong sales of its ADHD treatment Vyvanse.The London-listed company clinched its biggest acquisition to date in January, with a cash and shares deal to buy the specialist in rare blood conditions, cancers and immune system disorders. Chief Executive Flemming Ornskov said the deal, which is for